Saudi Arabia Pharma Distribution
we are doing a study on the pharmaceutical distribution practices adopted by major pharmaceutical manufacturers in saudi arabia
we are looking for subject matter experts for the following information:
1) to identify the top regional/nationalpharmaceutical distributors in saudi arabia
2) to understand the best practices associated while engaging with pharmaceutical distributors in saudi arabia
a. How do phharmaceutical manufacturers approach to evaluate the potential commercial distributors ?
B. Engagement model adopted by top pharmaceutical manufacturers for availing distribution services on a regional/country level
c. Pricing model adopted while engaging with pharmaceutical distributors in saudi arabia
d. What are the various compensation and incentives( monetary/non-monetary) provided by pharmaceutical manufacturers to distributors
e. Any relevant case studies to highlight prevalent best practices in distribution adopted by pharmaceutical companies
please let me know if you are intrested in this engagement and your comfort level in addressing these questions+27 Other Responses
Pharma Qualitative Study
We are seeking highly specialized experts with experience in the life sciences industry - must meet below specifications
location: usa - san fransisco bay area, los angeles, philadelphia, new york, boston.
Industry: pharmaceuticals, contract development and manufacturing organizations (cdmos)/clinical research organizations (cros), and life science market research.
Testing availability: late june - early july
study 2: qualitative study - one on one either telephonic or in-person interviews
cost estimates for both tdi (telephonic interviews) and idi (in person interviews) with 8 respondents, 2 each from clinical trial supply managers/coordinators/directors, procurement contacts / outsourcing managers / directors, clinical / pre-clinical teams, senior executives (pharma/biotech/cro)
**expert's job titles**:
1) clinical trial supply managers / coordinators / directors
2) procurement contacts / outsourcing managers / directors
3) clinical / pre-clinical teams
4) senior executives
**experts must have a clear understanding of the following topics (doesn't have to be an expert at each level, but at least one, also a basic understanding of others)**:
a. Api services & chemical development – all stages of drug development for small molecules, potent and cytotoxic compounds, and peptides
b. Pharmaceutical development – development cycle of clinical candidate into an optimum formulation and clinical stages manufacturing
c. Analytical services – analytical services supporting drug substance (api) and drug product development including cmc regulatory filings
d. Clinical trial supply – clinical supplies, packaging, distribution and delivery of clinical protocols, supply chain management.
E. Clinical technologies - solutions for patient enrollment, screening randomization, drug assessment etc.
F. Commercial services – api supply, manufacturing, testing and packaging to end-user distribution.+18 Other Responses
We are looking for an upstream process development specialist and process engineer in the development of pharmaceutical and biotechnology processes to meet we acquire, assess, or rapidly and economically develop process technology or production capabilities needed. The expert would able to guide work (provide protocols and advise) or actively engage in small scale upstream (mammalian cell) development if it needed, it including, fermentation process development, media optimization, scale-up technology, designs production method. In addition, this expert shall experience in commercial fermentation process, installed equipment, a cost evaluation and process improvements development for productivity and process robustness. This expert will also be expected to prepare final report, present data at internal meetings and external scientific conferences, and publish findings in respected peer reviewed journals. A significant hands-on, laboratory-based effort will be expected.+30 Other Responses
We have an extremely tax efficient vehicle for pharma investments and a client bank of potential investors. We are looking to create a pharma holding company with a couple of industry experts to assist in identifying phama investments. We are looking for investments that have been taken to a certain level and where an additional investment through a further development and exploitation agreement might prove successful. We would expect most investments to fail but would hope for a couple to be successful. There has to be commercial opportunity in each investment. This sounds unusual but because of the nature of the tax planning, the model still works. We would expect the industry experts to hold non exec positions in the pharma hold co, assist with identifying and appraising investment opportunities and overseeing the development and exploitation agreement. Non exec fees would be payable plus an upside in the share of any successful investments.
I am an ex big 4 chartered accountant and succesful serial entrepreneur and the team also consists of a top uk tax planning lawyer and an ex investment banker.+83 Other Responses